WANBURYWANBURY Forensic Risk Analysis

Pharmaceuticals
Risk ClassWatch
Market CapN/A
Primary DriverBalance Sheet Stress
Flagium AI Risk Score
Early signs of stress detected. Not yet widespread, but initial deterioration is visible.
25 / 100
+5 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in balance sheet stress. This suggests a building risk profile. Risk is increasing at a faster pace.

65.7th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
₹258▼3.21%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress
+14.8 pts
Growth Sustainability
+10.0 pts
Final Composite Risk25 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 5 → 25 over 13 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Inventory Stress
  • Relative Growth Weakness
  • Industrial Margin Stress
What to Watch Next Quarter
  • Working capital efficiency
  • Debt growth
  • Operating profit margins

Active Risk Objects (9)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 5 Years
More Detail
Impact Weight10/15
MomentumPersistent
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 32.4%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Operating Leverage Stress
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight10/15
MomentumDecaying
Last SignalQ4 FY2025
Expenses are consistently growing faster than revenues, creating operational pressure.

"Debt servicing metrics have improved recently. The company is actively deleveraging."

Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 6 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ3 FY2025
WANBURY: Low Interest Coverage Ratio of 1.13x in FY2025 Q3 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Inventory Stress
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight15/15
MomentumPersistent
Last SignalQ4 FY2026
Inventory growth (34.4%) significantly outpaced revenue growth (-5.2%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Negative FCF Streak
⚖️ Governance SignalsAnnualActive for 1 Years
More Detail
Impact Weight6/15
MomentumAccelerating
Last SignalFY2026
WANBURY: Negative Free Cash Flow for last 3 consecutive years.

"High capital expenditure and low OCF are draining cash. Debt levels may rise sharply."

Cash Conversion Deficit
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight6/15
MomentumPersistent
Last SignalFY2026
WANBURY: OCF below Net Profit in 3/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Relative Growth Weakness
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight12/15
MomentumDecaying
Last SignalQ3 FY2025
Revenue growth consistently lags behind sector median (12.8%).

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Profit Collapse
📊 Earnings QualityQuarterlyActive for 2 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ3 FY2025
WANBURY: Net Profit collapsed by 88.1% from FY2024 Q3 to FY2025 Q3.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Industrial Margin Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ1 FY2026
WANBURY: EBITDA margin compressed by 2.4 bps YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)5.177.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+41.0+47.0📈 CRITICAL
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹258(-3.21%)
1M Divergence-0.8%
1 Week-9.77%
1 Month+1.46%
6 Months+4.94%
1 Year-13.45%
2 Year+72.81%
3 Year+406.38%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The risk profile is Early Signals and currently deteriorating. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.

WANBURY • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.61%
Trend QualityStabilizing
Phase Progression
Phase Progression Score50%
Readiness LabelModerate (Transition Potential Building)
Probability of Advancing61%
CoinTree Momentum
Composite Z-Score-0.1480σ
Weakening momentum trend
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#1303 of 2716
Top 47.97% in momentum strength
Timeframe Sparklines
1W-9.8%
1M+1.5%
6M+4.9%
Weinstein Indicators
150 DMA₹243.54
200 DMA₹247.8
150 DMA Slope+0.8630%Rising
Relative Strength+10.39%Leading
Relative Turnover (RTR)0.7629
ParticipationWeak

PEER COMPARISON

Ranked comparison against sector peers

This company shows higher risk compared to the Sector Mean (19).
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

WANBURYWANBURY
25 Risk
Sector %ile66th
Delta+5
Active Flags9
Accel+1
Balance Sheet Stress

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

BALAXIBALAXI PHARMACEUTICALS LIMITED
45 Risk
Sector %ile96th
Delta+10
Active Flags40
Accel+1
Balance Sheet Stress

Moderate Deterioration

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
2.625.8th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
00th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Working Capital Expansion

2026

Inventory Stress

2026

Working Capital Expansion

2026

Inventory Stress

2026

Industrial Margin Stress

2026

Negative FCF Streak

2026

Cash Conversion Deficit

2025

Operating Leverage Stress

2025

Working Capital Expansion

2025

Relative Growth Weakness

2025

Operating Leverage Stress

2025

Operating Leverage Stress

2025

Working Capital Expansion

2025

Cash Conversion Deficit

2024

Inventory Stress

2024

Working Capital Expansion

2024

Cash Conversion Deficit

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20266516632215
FY20256033126173
FY2024579564110
FY2023501-102064